These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8652830)

  • 21. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
    Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
    Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity.
    Kushner BH; Cheung NK
    Blood; 1992 Mar; 79(6):1484-90. PubMed ID: 1347707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.
    Elsässer D; Valerius T; Repp R; Weiner GJ; Deo Y; Kalden JR; van de Winkel JG; Stevenson GT; Glennie MJ; Gramatzki M
    Blood; 1996 May; 87(9):3803-12. PubMed ID: 8611706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo.
    Gill I; Agah R; Hu E; Mazumder A
    Cancer Res; 1989 Oct; 49(19):5377-9. PubMed ID: 2788499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of alemtuzumab on neoplastic B cells.
    Golay J; Manganini M; Rambaldi A; Introna M
    Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inducible production of interleukin-6 by human polymorphonuclear neutrophils: role of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha.
    Cicco NA; Lindemann A; Content J; Vandenbussche P; Lübbert M; Gauss J; Mertelsmann R; Herrmann F
    Blood; 1990 May; 75(10):2049-52. PubMed ID: 1692493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
    Caron PC; Lai LT; Scheinberg DA
    Clin Cancer Res; 1995 Jan; 1(1):63-70. PubMed ID: 9815888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes.
    Kushner BH; Cheung NK
    Cancer Res; 1991 Sep; 51(18):4865-70. PubMed ID: 1654202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2.
    Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf I
    Cytokine; 2000 Jun; 12(6):756-61. PubMed ID: 10843759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma.
    Kushner BH; Cheung NK
    Blood; 1989 May; 73(7):1936-41. PubMed ID: 2653466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.
    van der Kolk LE; de Haas M; Grillo-López AJ; Baars JW; van Oers MH
    Leukemia; 2002 Apr; 16(4):693-9. PubMed ID: 11960351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granulocyte- and granulocyte-macrophage colony-stimulating factors enhance neutrophil cytotoxicity toward HIV-infected cells.
    Baldwin GC; Fuller ND; Roberts RL; Ho DD; Golde DW
    Blood; 1989 Oct; 74(5):1673-7. PubMed ID: 2477084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
    Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M
    Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.
    Masucci G; Wersäll P; Ragnhammar P; Mellstedt H
    Cancer Immunol Immunother; 1989; 29(4):288-92. PubMed ID: 2665935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G.
    Ottonello L; Epstein AL; Mancini M; Dapino P; Dallegri F
    J Leukoc Biol; 2004 Jan; 75(1):99-105. PubMed ID: 14525961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
    Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
    Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
    Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.